Navigation Links
NIBIB invests in quantum research

The National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health (NIH), today announced the award of more than $12 million in grants to support research and development of potentially high-impact, innovative technologies to advance health care.

The new grants will fund four investigators in developing groundbreaking technologies: disposable microchips for the diagnosis of metastatic lung cancer, a bio-artificial kidney to eliminate dialysis procedures, insulin-producing cells to treat diabetes, and nanoparticles that selectively leave the blood and bind to cancer cells to assist in removal of brain tumors.

This innovative program from the NIBIB promises to harness the power of technological discovery and team science to translate new knowledge into practical healthcare benefits for our nation, said Elias A. Zerhouni, M.D., NIH director.

The overall goal of the NIBIB Quantum Grants program is to make a profound (quantum level) advance in health care by funding research on targeted projects that will develop new technologies and modalities for the diagnosis, treatment, or prevention of disease.

We are excited to be awarding these Quantum Grants to four excellent researchers and their interdisciplinary teams, said NIBIB director Roderic I. Pettigrew, Ph.D., M.D. We look forward to watching the extraordinary results that will be achieved as these studies progress. All four of these projects have the potential to significantly improve the current practice of medicine.

Anthony Atala, M.D., Wake Forest University Health Sciences
$3.2 million (3 years)
Insulin Producing Cells from Amniotic Stem Cells for Diabetes Therapy

Diabetes impacts the individuals afflicted and society as a whole due to the significant complications associated with using existing insulin treatment strategies. The aim of this project is to develop a new source of insulin secreting cells as a replacement strategy for treating diabetes. Transplantation of pancreatic islets to restore insulin production is promising; however, the donor pancreata are in short supply and do not meet medical needs. The development of these tissue engineered islets will provide a new source of insulin-producing cells and help realize the full potential of cell therapy for diabetes.

Raoul Kopelman, Ph.D., University of Michigan at Ann Arbor
$2.6 million (3 years)
Nanoparticle Enabled Intraoperative Imaging and Therapy

Brain cancer is one of the most lethal forms of cancer, and is diagnosed in over 43,000 new patients each year. The goal of this project is to improve surgical resection and treatment options for brain cancer patients. Dr. Kopelman and his team will develop nanoparticles that selectively leave the blood and bind to cancer cells. These nanoparticles will aid in the visualization of tumors to allow for maximal surgical resection of tumor mass and also facilitate nonsurgical destruction of the residual cancer cells that are remote or extend from the tumor mass. This may achieve significant improvement in treatment of brain tumors.

Shuvo Roy, Ph.D., Cleveland Clinic Lerner College of Medicine-CWRU
$3.2 million (3 years)
Miniaturized Implantable Renal Assist Device for Total Renal Replacement Therapy

End stage renal disease is a significant global health problem. Donor kidneys for transplantation are in short supply, with dialysis and filtration as the only alternative treatment. This investigator and his team will develop a miniaturized, implantable, and self-regulating bio-artificial kidney that takes the dialysis machinery and integrates it into a miniaturized implantable device. The successful development of this bio-artificial kidney would provide an alternative to the majority of the dialysis procedures performed annually in the U.S.

Mehmet Toner, Ph.D., Massachusetts General Hospital
$3.4 million (3 years)
Point-of-Care Microfluidics in Lung Cancer

The goal of this project is to develop a point-of-care microchip device that can determine the type, severity, and aggressiveness of a wide range of cancers by detecting tumor cells that are circulating in the blood stream. Dr. Toner and his team will develop a new disposable microchip technology capable of separating specific circulating tumor cells from whole human blood at concentrations as low as one in a billion. Detecting the presence of these tumor cells at such low concentrations enables earlier intervention in the treatment of metastatic lung cancer, which remains the leading cause of cancer death in the U.S. This point of care test can potentially transform patient care through early molecular diagnosis of lung cancer and identification of new biomarkers with which to track disease progression.


Contact: Cheryl Fee
NIH/National Institute of Biomedical Imaging & Bioengineering

Related biology news :

1. Canadas new government invests $200M in the fight against the mountain pine beetle
2. Quantum Dots Research Leads to New Knowledge about Protein Binding in Plants
3. Quantum dots provide a faster, more sensitive method for detecting respiratory viral infections
4. Method slashes quantum dot costs by 80 percent
5. New nanosensor uses quantum dots to detect DNA
6. Connect the Quantum Dots
7. Quantum dots reviewed -- Could these nanoparticles hold the cure to cancer?
8. First Quantum Grant to fund stem cell repair of damage from stroke
9. Protein enables discovery of quantum effect in photosynthesis
10. Researchers discover way to make cells in the eye sensitive to light
11. Columbia research lifts major hurdle to gene therapy for cancer
Post Your Comments:
(Date:10/26/2015)... , Oct. 26, 2015  Delta ID Inc., a ... to mobile and PC devices, announced its ActiveIRIS® technology ... arrows NX F-02H launched by NTT DOCOMO, INC in ... is the second smartphone to include iris recognition technology, ... ARROWS NX F-04G in May 2015, world,s first smartphone ...
(Date:10/23/2015)... GOLETA, California , October 23, 2015 ... and SensoMotoric Instruments (SMI) announce a mobile plug and ... captured during interactive real-world tasks SensoMotoric Instruments ... of their established wearable solutions for eye tracking and ... behavior captured with SMI Eye Tracking Glasses 2w ...
(Date:10/22/2015)... Oct. 22, 2015  Synaptics (NASDAQ: SYNA ), a leading ... first quarter ended September 30, 2015. --> ... fiscal 2016 grew 66 percent over the comparable quarter last year ... 2016 was $23.8 million, or $0.62 per diluted share. ... the first quarter of fiscal 2016 grew 39 percent over the ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... LAVAL, QC , Nov. 24, 2015 /CNW Telbec/ - ... the "Corporation") announced today that Mr. Pierre Laurin , ... a corporate presentation at the upcoming Piper Jaffray 27 th ... York Palace Hotel, on December 1-2, 2015. ... be available for one-on-one meetings throughout the day. The presentation ...
(Date:11/24/2015)... NEW YORK , November 24, 2015 /PRNewswire/ ... Bristol-Myers Squibb in a European ... Company in which the companies will work closely together ... other areas of unmet medical need. The collaboration is underpinned ... the latest LSP fund. This is the first investment by ...
(Date:11/23/2015)... Ceres, Inc . (Nasdaq: CERE ), an agricultural ... year ended August 31, 2015 and provided an update ... --> During fiscal year 2015, Ceres refocused its ... better balance of yield, energy and nutrition. Among other ... crop input providers and made significant progress in advancing ...
(Date:11/23/2015)... , November 23, 2015 The ... to develop daclatasvir for 112 ...   --> --> The ... a hepatitis C medicine, signing an agreement with Bristol-Myers Squibb ... help cure multiple genotypes of the HCV virus.  The royalty-free ...
Breaking Biology Technology: